| Literature DB >> 30327640 |
Qiwei Chen1, Xiaowei Gong1, Fuying Zheng1, Guo Ji1, Shengdou Li1, Laszlo Stipkovits2, Susan Szathmary2, Yongsheng Liu1.
Abstract
The number of multidrug-resistant strains of Riemerella anatipestifer continues to increase, and new strategies for the treatment of associated infections are necessary. Recently, numerous studies have shown that efflux pumps (EPs) play key roles in universal bacterial mechanisms that contribute to antibiotic resistance. In addition, studies have shown that the effects of antibiotics that are subjected to efflux can be reinforced by their combined use with efflux pump inhibitors (EPIs). Unfortunately, the role of the efflux system in R. anatipestifer remains barely understood. In this study, we evaluated the role of EPs and resistance genes in the resistance generated by clinical strains of R. anatipestifer to antibiotics. A set of 10 R. anatipestifer strains were characterized by drug resistance, associated resistance genes, and antibiotic profiles in the presence and absence of EPIs. Efflux activity was studied on a real time basis through a fluorometric method. Quantification of the levels of mRNA transcription of efflux pump genes (EPGs) was determined by RT-qPCR. Several approaches (detection of resistance genes, drug susceptibility testing, and growth kinetics analysis) were used to assess the correlation between the effect of the EPIs and the resistance levels. Analysis of the R. anatipestifer growth inhibition tests showed that the antibiotic activity was enhanced by the synergy of EPIs. Among the various resistance genes that confer antibiotic resistance, different minimum inhibitory concentrations (MICs) were observed. The different levels of resistance were reduced by EPIs. Real time fluorometry showed that all the R. anatipestifer strains presented inherent efflux activity, conferring varying levels of inhibition in the presence of EPIs. Moreover, 15 EPGs were overexpressed in the presence of antibiotics. The addition of EPIs to antibiotics led to downregulation in the expression of some EPGs and a simultaneous increase in drug resistance and sensitivity. These results demonstrated the contribution of these EPs in the resistant phenotype of the clinical strains of R. anatipestifer that are under investigation, independently of the resistant genotype of the respective strains. Intrinsic efflux activity was possibly linked to the evolution of resistance in multidrug-resistant isolates of R. anatipestifer. Furthermore, the inhibition of EPs by EPIs could enhance the clinical effects of antibiotics.Entities:
Keywords: Riemerella anatipestifer; drug resistance; efflux pump; efflux pump inhibitors; synergism
Year: 2018 PMID: 30327640 PMCID: PMC6174861 DOI: 10.3389/fmicb.2018.02136
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Categorization of the R. anatipestifer strains that were studied according to their serotype, resistance pattern, and phenotype.
| RA01 | ATCC | 6 | None | Pan-Susceptible |
| RA70 | Isolate | 8 | SMT | Monoresistant to SMT |
| HN352 | Isolate | 6 | FLR | Monoresistantto FLR |
| RA66 | Isolate | 1 | ROX | Monoresistant to ROX |
| HN313 | Isolate | 2 | AMP | Monoresistant to AMP |
| HN333 | Isolate | 10 | QUO | Resistant to QUO |
| FS8 | Isolate | 1 | STR, KAN, GEN, SPE, TOB,SMT, TET, ROX | MDR |
| WF7 | Isolate | 2 | STR, KAN, GEN, TOB, CIP, ENO, FLR, TET, OXT | MDR |
| GD01 | Isolate | 2 | STR, KAN, GEN, SPE, AMK, TOB, NA, CIP, ENO, AMP, CEF, CHL, FLR, SMT, TET | XDR |
| SD314 | Isolate | 7 | STR, KAN, GEN, SPE, AMK, NEO, TOB, NA, CIP, AMP, FLR, SMT, ROX, TET | XDR |
STR, streptomycin; KAN, kanamycin; GEN, gentamicin; SPE, spectinomycin; AMK, amikacin; NEO, neomycin; TOB, tobramycin; NA, nalidixic acid; CIP, ciprofloxacin; ENO, enrofloxacin; AMP, ampicillin; CEF, cefoxitin; CHL, chloramphenicol; FLR, florfenicol; SMT, sulfamonomethoxine; ROX, roxithromycin; TET, tetracycline; OXT, oxytetracycline; QUO, quinolones (NA, CIP, ENO). ATCC, American Type Culture Collection; Reference strains, RA01, ATCC11845; MDR, multidrug-resistance, resistant to at least three classes of antimicrobial agents; XDR, extensive drug-resistance, resistant to at least five classes of antimicrobial agents.
MIC of antibiotics and EB for the R. anatipestifer strains studied.
| Susceptible | |||||||||||||||||||
| RA01 | 8 | 4 | 2 | 2 | 2 | 8 | 2 | 4 | 0.125 | 0.125 | 1 | 0.25 | 0.5 | 0.25 | 8 | 0.125 | 0.25 | 0.5 | 0.6 |
| SMTR | |||||||||||||||||||
| RA70 | 16 | 16 | 8 | 8 | 4 | 32 | 16 | 8 | 0.25 | 0.125 | 1 | 0.5 | 0.5 | 0.5 | 64 | 0.125 | 0.25 | 2 | 1.0 |
| FLRR | |||||||||||||||||||
| HN352 | 16 | 16 | 16 | 32 | 32 | 32 | 8 | 8 | 0.25 | 0.5 | 4 | 0.25 | 8 | 16 | 32 | 2 | 2 | 2 | 1.0 |
| ROXR | |||||||||||||||||||
| RA66 | 8 | 16 | 8 | 32 | 16 | 32 | 16 | 32 | 2 | 2 | 2 | 0.5 | 2 | 1 | 64 | 32 | 4 | 4 | 1.0 |
| AMPR | |||||||||||||||||||
| HN313 | 32 | 32 | 16 | 64 | 8 | 64 | 32 | 32 | 1 | 1 | 16 | 2 | 2 | 0.5 | 16 | 16 | 4 | 2 | 1.0 |
| QUOR | |||||||||||||||||||
| HN333 | 16 | 16 | 32 | 32 | 32 | 32 | 64 | 64 | 8 | 8 | 1 | 0.25 | 2 | 1 | 16 | 8 | 2 | 1 | 1.2 |
| MDR | |||||||||||||||||||
| FS8 | 64 | 64 | 64 | 64 | 8 | 16 | 64 | 16 | 4 | 1 | 1 | 0.25 | 1 | 0.5 | 64 | 16 | 16 | 8 | 2.0 |
| WF7 | 64 | 64 | 64 | 16 | 16 | 16 | 64 | 16 | 4 | 4 | 1 | 0.5 | 2 | 8 | 16 | 2 | 8 | 8 | 2.0 |
| XDR | |||||||||||||||||||
| GD01 | 64 | 64 | 64 | 64 | 32 | 16 | 64 | 64 | 4 | 4 | 16 | 4 | 32 | 8 | 64 | 0.5 | 8 | 2 | 2.0 |
| SD314 | 64 | 64 | 64 | 64 | 32 | 64 | 64 | 64 | 4 | 1 | 8 | 1 | 4 | 2 | 64 | 8 | 8 | 2 | 2.0 |
STR, streptomycin; KAN, kanamycin; GEN, gentamicin; SPE, spectinomycin; AMK, amikacin; NEO, neomycin; TOB, tobramycin; NA, nalidixic acid; CIP, ciprofloxacin; ENO, enrofloxacin; AMP, ampicillin; CEF, cefoxitin; CHL, chloramphenicol; FLR, florfenicol; SMT, sulfamonomethoxine; ROX, roxithromycin; TET, tetracycline; OXT, oxytetracycline; EB, Ethidium bromide. Green represents sensitivity; red represents resistance; purple represents intermediate.
Characteristics of drug-resistant genes of R. anatipestifer isolates used in this study.
| Susceptible | ||||||||
| RA01 | – | – | WT | WT | WT | WT | – | |
| SMTR | ||||||||
| RA70 | – | WT | WT | WT | WT | – | ||
| FLRR | ||||||||
| HN352 | – | Ser83Ile | WT | WT | WT | – | ||
| ROXR | ||||||||
| RA66 | – | WT | WT | WT | WT | – | ||
| AMPR | ||||||||
| HN313 | – | – | WT | WT | WT | WT | – | |
| QUOR | ||||||||
| HN333 | – | Ser83Ile | Ser121Phe | Gly313Ser | WT | |||
| MDR | ||||||||
| FS8 | – | Asp87His | WT | WT | WT | – | ||
| WF7 | Ser83Ile | WT | Gly313Ser | WT | ||||
| XDR | ||||||||
| GD01 | – | Ser83Ile | WT | WT | WT | – | ||
| SD314 | – | Ser83Arg | WT | Gly313Ser | WT | |||
SMT, sulfamonomethoxine; AMK, amikacin; ROX, roxithromycin; AMP, ampicillin; QUO, quinolones (NA, CIP, ENO). MDR, multidrug-resistance; XDR, extensive drug-resistance. WT, wild type sequence. QRDR, quinolone resistance determining regions; PMQR, plasmid-mediated quinolone resistance.
Quantitative drug susceptibility testing in the presence and absence of efflux inhibitors.
| SMT | No EI | 64 | – | – | – | – | 64 | – | – | – |
| +CCCP | 32 | – | – | – | – | 16 | – | – | – | |
| +PAβN | 8 | – | – | – | – | 4 | – | – | – | |
| FLR | No EI | – | 16 | – | – | – | – | 8 | 8 | 2 |
| +CCCP | – | 0.25 | – | – | – | – | 0.5 | 0.25 | 0.25 | |
| +PAβN | – | 0.5 | – | – | – | – | 1 | 1 | 1 | |
| ROX | No EI | – | – | 32 | – | – | 16 | – | – | 8 |
| +CCCP | – | – | 2 | – | – | 2 | – | – | 1 | |
| +PAβN | – | – | 8 | – | – | 4 | – | – | 4 | |
| AMP | No EI | – | – | – | 16 | – | – | – | 16 | 8 |
| +CCCP | – | – | – | 4 | – | – | – | 16 | 8 | |
| +PAβN | – | – | – | 1 | – | – | – | 1 | 0.25 | |
| CIP | No EI | – | – | – | – | 8 | 4 | 4 | 4 | 4 |
| +CCCP | – | – | – | – | 4 | 4 | 4 | 1 | 4 | |
| +PAβN | – | – | – | – | 2 | 1 | 0.125 | 0.125 | 1 | |
| ENO | No EI | – | – | – | – | 8 | – | – | – | – |
| +CCCP | – | – | – | – | 0.5 | – | – | – | – | |
| +PAβN | – | – | – | – | 0.5 | – | – | – | – | |
| OXT | No EI | – | – | – | – | – | – | 8 | – | – |
| +CCCP | – | – | – | – | – | – | 0.5 | – | – | |
| +PAβN | – | – | – | – | – | – | 4 | – | – | |
| CHL | No EI | – | – | – | – | – | – | – | 32 | – |
| +CCCP | – | – | – | – | – | – | – | 2 | – | |
| +PAβN | – | – | – | – | – | – | – | 8 | – | |
| AMK | No EI | – | – | – | – | – | – | – | 32 | 32 |
| +CCCP | – | – | – | – | – | – | – | 1 | 2 | |
| +PAβN | – | – | – | – | – | – | – | 8 | 16 | |
| NEO | No EI | – | – | – | – | – | – | – | – | 64 |
| +CCCP | – | – | – | – | – | – | – | – | 4 | |
| +PAβN | – | – | – | – | – | – | – | – | 32 | |
SMT, sulfamonomethoxine; FLR, florfenicol; ROX, roxithromycin; AMP, ampicillin; CIP, ciprofloxacin; ENO, enrofloxacin; OXT, oxytetracycline; CHL, chloramphenico; AMK, amikacin; NEO, neomycin; QUO, quinolones (NA, CIP, ENO). *The lowest concentration tested corresponded to the critical concentration for each antibiotic (see section Materials and Methods for details). MDR, multidrug-resistance; XDR, extensive drug-resistance. CCCP (5μg/mL), carbonyl cyanide-m-chlorophenylhydrazone; PAβN (40μg/mL), Phe-Arg-β-naphthylamide.
Figure 1Quantification of the relative mRNA expression levels of a panel of EPGs in mono-resistant strains. Strains were grown in the presence of half MIC of each antibiotic; CCCP (5 μg/mL) and PAβN (40 μg/mL), showed no effects on the growth of R. anatipestifer isolates. The MICs of the antibiotics and EPIs were determined for each strain and are presented in Table 4. Change in the level of transcription of EPGs was measured as fold change normalized to recA gene expression and was subsequently calculated as log2-fold change that is relative to the untreated cell culture. Levels of significance were set as follows: *P < 0.05 was considered statistically significant and **P < 0.01, ***P < 0.001, and ****P < 0.0001 were all considered highly significant.
Figure 2Quantification of the relative mRNA expression levels of a panel of EPGs in multidrug-resistant strains. Strains were grown in the presence of half MIC of each antibiotic; CCCP (5 μg/mL) and PAβN (40 μg/mL) showed no effects on the growth of R. anatipestifer isolates. The MICs of the antibiotics and EPIs were determined for each strain and are presented in Table 4. Change in the level of transcription of EPGs was measured as fold change normalized to recA gene expression and was subsequently calculated as log2-fold change that is relative to the untreated cell culture. Levels of significance were set as follows: *P < 0.05 was considered statistically significant, and **P < 0.01, ***P < 0.001, and ****P < 0.0001 were all considered highly significant.
Figure 3Quantification of the relative mRNA expression levels of a panel of EPGs in GD01 strains. Strains were grown in the presence of half MIC of each antibiotic; CCCP (5 μg/mL) and PAβN (40 μg/mL) showed no effects on the growth of R. anatipestifer isolates. The MICs of the antibiotics and EPIs were determined for each strain and are presented in Table 4. Change in the level of transcription of EPGs was measured as fold change normalized to recA gene expression and was subsequently calculated as log2-fold change that is relative to the untreated cell culture. Levels of significance were set as follows: *P < 0.05 was considered statistically significant, and **P < 0.01, ***P < 0.001, and ****P < 0.0001, were all considered highly significant.
Figure 4Quantification of the relative mRNA expression levels of a panel of EPGs in SD314 strains. Strains were grown in the presence of half MIC of each antibiotic; CCCP (5 μg/mL) and PAβN (40 μg/mL) showed no effects on the growth of R. anatipestifer isolates. The MICs of the antibiotics and EPIs were determined for each strain and are presented in Table 4. Change in the level of transcription of EPGs was measured as fold change normalized to recA gene expression and was subsequently calculated as log2-fold change that is relative to the untreated cell culture. Levels of significance were set as follows: *P < 0.05 was considered statistically significant, and **P < 0.01, ***P < 0.001, and ****P < 0.0001 were all considered highly significant.
Figure 5Quantitative drug susceptibility testing of the antibiotics for the R. anatipestifer strains, in the presence or absence of each EPI. CCCP (5 μg/mL) and PAβN (40 μg/mL) showed no effects on the growth of R. anatipestifer isolates. Strains were grown in the presence of half MIC of each antibiotic as follows: RA70 (32 μg/mL) and FS8 (32 μg/mL) were exposed to SMT, HN352 (8 μg/mL), WF7 (4 μg/mL), GD01 (4 μg/mL), and SD314 (1 μg/mL) were exposed to FLR; GD01 (16 μg/mL) was exposed to CHL; WF7 (4 μg/mL) was exposed to OXT; GD01(16 μg/mL) and SD314 (16 μg/mL) were exposed to AMK; SD314 (32 μg/mL) was exposed to NEO. The figure showed that the R. anatipestifer strains grew slowly (between 1 and 12 h) because of the synergistic effect of the antibiotics and EPIs.
Figure 6Quantitative drug susceptibility testing of antibiotics for the R. anatipestifer strains, in the presence or absence of each EPI. CCCP (5 μg/mL) and PAβN (40 μg/mL) showed no effects on the growth of R. anatipestifer isolates. Strains were grown in the presence of half MIC of each antibiotic as follows: RA66 (16 μg/mL), FS8 (8 μg/mL), and SD314 (4 μg/mL) were exposed to ROX; HN313 (8 μg/mL), GD01 (8 μg/mL), and SD314 (4 μg/mL) were exposed to AMP; HN333 (4 μg/mL) was exposed to ENO; HN333 (4 μg/mL), FS8 (2 μg/mL), WF7 (2 μg/mL), GD01 (2 μg/mL), and SD314 (2 μg/mL) were exposed to CIP. The figure showed that the R. anatipestifer strains grew slowly (between 1 and 12 h) because of the synergistic effect of the antibiotics and EPIs.